Is AKRO A Good Stock To Buy Now?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their...
Akero Therapeutics Inc. (AKRO)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 2,322,557 | $59,922 | -1% | 0.72% |
| 2. | Alkeon Capital Management Panayotis Takis Sparaggis | 2,287,630 | $59,021 | +1% | 0.12% |
| 3. | Cormorant Asset Management Bihua Chen | 742,549 | $19,158 | -14% | 0.45% |
| 4. | Point72 Asset Management Steve Cohen | 705,000 | $18,189 | +393% | 0.08% |
| 5. | Vivo Capital Albert Cha And Frank Kung | 633,426 | $16,342 | +11% | 0.72% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.00 | 415,000 | Large Shareholder | 5,830,203 | 2020-07-10 | Filing | |
| $36.00 | 415,000 | Large Shareholder, Director | 5,830,203 | 2020-07-10 | Filing | |
| $16.00 | 270,000 | Director | 505,099 | 2019-06-24 | Filing | |
| $16.00 | 270,000 | Large Shareholder | 505,099 | 2019-06-24 | Filing | |
| $16.00 | 250,000 | Director | 250,000 | 2019-06-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.92 | 200 | Officer | 176,230 | 2021-02-01 | Filing | |
| $29.19 | 2,855 | Officer | 176,430 | 2021-02-01 | Filing | |
| $28.12 | 10,000 | Officer | 179,285 | 2021-01-08 | Filing | |
| $26.00 | 100 | Officer | 181,785 | 2021-01-04 | Filing | |
| $25.27 | 2,960 | Officer | 181,885 | 2021-01-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 8,400 | $216,720 | 0% | |
| 2. | 5,830,203 | $168,435 | 13% | |
| 3. | 3,493,419 | $90,136 | 0.04% | |
| 4. | 2,444,311 | $63,063 | 5.56% | |
| 5. | 1,670,510 | $43,099 | 0% |
News See All
Is Akero Therapeutics, Inc. (AKRO) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F...
Hedge Funds Are Dumping Akero Therapeutics, Inc. (AKRO)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and...
Hedge Funds Have Never Been This Bullish On Akero Therapeutics, Inc. (AKRO)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these...
Hedge Fund and Insider Trading News: Kyle Bass, Elliott Management, Arlington Capital, Akero Therapeutics Inc (AKRO), Lattice Semiconductor Corp (LSCC), and More
Elliott Management Corp. had built a position in Allergan Plc and was pushing to split the company before AbbVie Inc. agreed to acquire it for $63 billion, according to people familiar with the matter...
Billionaire Hedge Funds
